AURA vs. TRML, SLDB, AVXL, TNYA, REPL, CCCC, MGTX, CRBU, BDTX, and TCRX
Should you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Tourmaline Bio (TRML), Solid Biosciences (SLDB), Anavex Life Sciences (AVXL), Tenaya Therapeutics (TNYA), Replimune Group (REPL), C4 Therapeutics (CCCC), MeiraGTx (MGTX), Caribou Biosciences (CRBU), Black Diamond Therapeutics (BDTX), and TScan Therapeutics (TCRX). These companies are all part of the "biological products, except diagnostic" industry.
Tourmaline Bio (NASDAQ:TRML) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.
Aura Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aura Biosciences had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 3 mentions for Aura Biosciences and 2 mentions for Tourmaline Bio. Aura Biosciences' average media sentiment score of 0.93 beat Tourmaline Bio's score of 0.37 indicating that Tourmaline Bio is being referred to more favorably in the media.
Aura Biosciences received 2 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 46.15% of users gave Aura Biosciences an outperform vote.
Aura Biosciences' return on equity of -19.56% beat Tourmaline Bio's return on equity.
91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 5.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Tourmaline Bio currently has a consensus price target of $61.80, indicating a potential upside of 359.48%. Aura Biosciences has a consensus price target of $21.00, indicating a potential upside of 198.72%. Given Aura Biosciences' higher possible upside, equities analysts plainly believe Tourmaline Bio is more favorable than Aura Biosciences.
Tourmaline Bio has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.
Summary
Tourmaline Bio beats Aura Biosciences on 10 of the 14 factors compared between the two stocks.
Get Aura Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aura Biosciences Competitors List
Related Companies and Tools
